Granted Patent
E1
US 50,916 · App. 18/183,240 · Granted Jun 16, 2026
Methods for production of platelets from pluripotent stem cells and compositions thereof
A61K35/19C12N5/0644C12N2501/04C12N2501/20C12N2501/2306C12N2501/2309C12N2501/2311C12N2501/30C12N2501/40C12N2501/727C12N2501/734C12N2501/91C12N2506/11
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Methods for production of platelets from pluripotent stem cells, such as human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs) are provided. These methods may be performed without forming embryoid bodies or clusters of pluripotent stem cells, and may be performed without the use of stromal inducer cells. Additionally, the yield and/or purity can be greater than has been reported for prior methods of producing platelets from pluripotent stem cells. Also provided are compositions and pharmaceutical preparations comprising platelets, preferably produced from pluripotent stem cells.
Claims (45)
1 . A method for producing human megakaryocytes comprising:
(a) culturing human pluripotent stem cells under an adherent condition in culture medium that comprises bone morphogenetic protein 4, basic fibroblast growth factor, and vascular endothelial growth factor to form human hemogenic endothelial cells;
(b) culturing the human hemogenic endothelial cells in culture medium that comprises two or more factors selected from thrombopoietin, interleukin-3, and interleukin-6 to form human megakaryocyte progenitors; and
(c) culturing the human megakaryocyte progenitors under a non-adherent culture condition in culture medium that comprises thrombopoietin and one or more factor(s) selected from stem cell factor, interleukin-6, interleukin-9, and a ROCK inhibitor to form human megakaryocytes.
2 . The method of claim 1 , wherein the human pluripotent stem cells are human induced pluripotent stem cells.
3 . The method of claim 1 , wherein the human hemogenic endothelial cells are cultured in the presence of a BET inhibitor.
4 . The method of claim 3 , wherein the BET inhibitor is IBET151.
5 . The method of claim 3 , wherein the concentration of BET inhibitor is within a micromolar or submicromolar range.
6 . The method of claim 5 , wherein the concentration of BET inhibitor is 0.25 μM.
7 . The method of claim 1 , wherein the culture medium of step (b) comprises thrombopoietin, interleukin-3, and interleukin-6.
8 . The method of claim 1 , wherein the culture medium of step (c) comprises stem cell factor, thrombopoietin, interleukin-6, interleukin-9, and a ROCK inhibitor.
9 . The method of claim 8 , wherein the ROCK inhibitor is Y27632.
10 . The method of claim 1 , wherein the human hemogenic endothelial cells are differentiated from the human pluripotent stem cells under low oxygen conditions comprising 1% to 10% oxygen.
11 . The method of claim 10 , wherein the human hemogenic endothelial cells are differentiated from the human pluripotent stem cells under low oxygen conditions comprising 4% to 6% oxygen.
12 . The method of claim 1 , wherein the human megakaryocyte progenitors are cultured to form human megakaryocytes at a temperature between 38-40° C.
13 . The method of claim 1 , wherein the human hemogenic endothelial cells express CD31.
14 . The method of claim 1 , wherein the human megakaryocyte progenitors express CD41a.
15 . The method of claim 1 , wherein the step of culturing human pluripotent stem cells under an adherent condition comprises culturing human pluripotent stem cells on an extracellular matrix.
16 . The method of claim 1 , wherein the human pluripotent stem cells of step (a) are cultured under a feeder-free culture condition.
17 . A method for producing human megakaryocytes comprising:
(a) culturing human pluripotent stem cells under an adherent condition in culture medium that comprises bone morphogenetic protein 4, basic fibroblast growth factor, and vascular endothelial growth factor to form human hemogenic endothelial cells;
(b) culturing the human hemogenic endothelial cells in culture medium that comprises stem cell factor, thrombopoietin, Fms-related tyrosine kinase 3 ligand, interleukin-3, and interleukin-6 to form human megakaryocyte progenitors; and
(c) culturing the human megakaryocyte progenitors under a non-adherent culture condition in culture medium that comprises stem cell factor, thrombopoietin, interleukin-6, and interleukin-9 to form human megakaryocytes.
18 . The method of claim 17 , wherein the human hemogenic endothelial cells are cultured in the presence of a ROCK inhibitor and/or a BET inhibitor.
19 . A method for producing human megakaryocytes comprising:
(a) culturing human pluripotent stem cells under an adherent condition in culture medium that comprises bone morphogenetic protein 4, basic fibroblast growth factor, and vascular endothelial growth factor to form human hemogenic endothelial cells;
(b) culturing the human hemogenic endothelial cells in culture medium that comprises two or more factors selected from thrombopoietin, interleukin-3, interleukin-6, and Fms-related tyrosine kinase 3 to form human megakaryocyte progenitors; and
(c) culturing the human megakaryocyte progenitors under a non-adherent culture condition in culture medium that comprises thrombopoietin and one or more factor(s) selected from stem cell factor, interleukin-6, interleukin-9, and a ROCK inhibitor to form human megakaryocytes.
20 . The method of claim 19 , wherein the human pluripotent stem cells are human induced pluripotent stem cells.
21 . The method of claim 19 , wherein the human hemogenic endothelial cells are cultured in the presence of a BET inhibitor.
22 . The method of claim 19 , wherein the culture medium of step (b) comprises thrombopoietin, Fms-related tyrosine kinase 3 ligand, interleukin-3, and interleukin-6.
23 . The method of claim 19 , wherein the culture medium of step (c) comprises stem cell factor, thrombopoietin, interleukin-6, interleukin-9, and a ROCK inhibitor.
24 . The method of claim 19 , wherein the step of culturing human pluripotent stem cells under an adherent condition comprises culturing human pluripotent stem cells on an extracellular matrix.
25 . The method of claim 19 , wherein the human pluripotent stem cells of step (a) are cultured under a feeder-free culture condition.
26 . A method for producing human megakaryocytes comprising:
(a) culturing human pluripotent stem cells under an adherent condition in culture medium that comprises bone morphogenetic protein 4, basic fibroblast growth factor, and vascular endothelial growth factor to form human hemogenic endothelial cells;
(b) culturing the human hemogenic endothelial cells in culture medium that comprises two or more factors selected from thrombopoietin, interleukin-3, interleukin-6, and stem cell factor to form human megakaryocyte progenitors; and
(c) culturing the human megakaryocyte progenitors under a non-adherent culture condition in culture medium that comprises thrombopoietin and one or more factor(s) selected from stem cell factor, interleukin-6, interleukin-9, and a ROCK inhibitor to form human megakaryocytes.
27 . The method of claim 26 , wherein the human pluripotent stem cells are human induced pluripotent stem cells.
28 . The method of claim 26 , wherein the human hemogenic endothelial cells are cultured in the presence of a BET inhibitor.
29 . The method of claim 26 , wherein the culture medium of step (b) comprises thrombopoietin, stem cell factor, interleukin-3, and interleukin-6.
30 . The method of claim 26 , wherein the culture medium of step (c) comprises stem cell factor, thrombopoietin, interleukin-6, interleukin-9, and a ROCK inhibitor.
31 . The method of claim 26 , wherein the step of culturing human pluripotent stem cells under an adherent condition comprises culturing human pluripotent stem cells on an extracellular matrix.
32 . The method of claim 26 , wherein the human pluripotent stem cells of step (a) are cultured under a feeder-free culture condition.
33. The method of claim 17 , wherein the human hemogenic endothelial cells are cultured in the presence of a BET inhibitor.
Continuity (3)
Provisional Application
61787476
· Mar 15, 2013
Provisional Application
61740699
· Dec 21, 2012
References Cited (400)
US 5128259A
· Morgan
· 1992
[cited by applicant]
US 5599705A
· Cameron
· 1997
[cited by applicant]
US 5635387A
· Fei et al.
· 1997
[cited by applicant]
US 5649903A
· Deniega
· 1997
[cited by applicant]
US 5914268A
· Keller et al.
· 1999
[cited by applicant]
US 6429012B1
· Kraus et al.
· 2002
[cited by applicant]
US 6479286B1
· Nelson et al.
· 2002
[cited by applicant]
US 6602711B1
· Thomson et al.
· 2003
[cited by applicant]
US 7220584B2
· Thomson et al.
· 2007
[cited by applicant]
US 7282201B2
· Miura et al.
· 2007
[cited by applicant]
US 7374934B2
· Keller et al.
· 2008
[cited by applicant]
US 7455983B2
· Xu et al.
· 2008
[cited by applicant]
US 7476326B2
· Ahn et al.
· 2009
[cited by applicant]
US 7718420B2
· Kim et al.
· 2010
[cited by applicant]
US 7790458B2
· Xu et al.
· 2010
[cited by applicant]
US 8017393B2
· Lanza et al.
· 2011
[cited by applicant]
US 8252587B2
· Fong et al.
· 2012
[cited by applicant]
US 8263403B2
· Perry et al.
· 2012
[cited by applicant]
US 8372642B2
· Rajesh et al.
· 2013
[cited by applicant]
US 8535943B2
· Nakano et al.
· 2013
[cited by applicant]
US 8546141B2
· Nakauchi et al.
· 2013
[cited by applicant]
US 8822218B2
· Kimbrel et al.
· 2014
[cited by applicant]
US 8933071B2
· Crispino et al.
· 2015
[cited by applicant]
US 8962321B2
· Kimbrel et al.
· 2015
[cited by applicant]
US 9012221B2
· Baruch et al.
· 2015
[cited by applicant]
US 9074186B2
· Murphy et al.
· 2015
[cited by applicant]
US 9109202B2
· Spanholtz
· 2015
[cited by applicant]
US 9121008B2
· Tsai
· 2015
[cited by applicant]
US 9200254B2
· Eto et al.
· 2015
[cited by applicant]
US 9410123B2
· Lanza et al.
· 2016
[cited by applicant]
US 9655925B2
· Lowdell et al.
· 2017
[cited by applicant]
US 9763984B2
· Feng et al.
· 2017
[cited by applicant]
US 9938500B2
· Lanza et al.
· 2018
[cited by applicant]
US 9988602B2
· Lanza et al.
· 2018
[cited by applicant]
US 9988603B2
· Li et al.
· 2018
[cited by applicant]
US 9993503B2
· Feng et al.
· 2018
[cited by applicant]
US 20020035735A1
· Schatten et al.
· 2002
[cited by applicant]
US 20030153082A1
· Bhatia
· 2003
[cited by applicant]
US 20030166273A1
· Kaufman et al.
· 2003
[cited by applicant]
US 20030175954A1
· Shamblott et al.
· 2003
[cited by applicant]
US 20040013676A1
· Bae et al.
· 2004
[cited by applicant]
US 20040052771A1
· Lim
· 2004
[cited by applicant]
US 20040136973A1
· Huberman et al.
· 2004
[cited by applicant]
US 20040229350A1
· Strelchenko et al.
· 2004
[cited by applicant]
US 20050032210A1
· Sato et al.
· 2005
[cited by applicant]
US 20050042751A1
· Goldman et al.
· 2005
[cited by applicant]
US 20050153443A1
· Lanza et al.
· 2005
[cited by applicant]
US 20050176142A1
· Nakorn et al.
· 2005
[cited by applicant]
US 20050221482A1
· Burt et al.
· 2005
[cited by applicant]
US 20050221487A1
· Zon et al.
· 2005
[cited by applicant]
US 20060099198A1
· Thomson et al.
· 2006
[cited by applicant]
US 20070042344A1
· Choi et al.
· 2007
[cited by applicant]
US 20070077654A1
· Thomson
· 2007
[cited by applicant]
US 20070141703A1
· Stanley et al.
· 2007
[cited by applicant]
US 20070218552A1
· Giarratana et al.
· 2007
[cited by applicant]
US 20070243608A1
· Kyba et al.
· 2007
[cited by applicant]
US 20070298496A1
· Kuo et al.
· 2007
[cited by applicant]
US 20080003674A1
· Slukvin et al.
· 2008
[cited by applicant]
US 20080014180A1
· Lanza et al.
· 2008
[cited by applicant]
US 20080014183A1
· Okano et al.
· 2008
[cited by applicant]
US 20080057041A1
· Chung et al.
· 2008
[cited by applicant]
US 20080108044A1
· Rajesh et al.
· 2008
[cited by applicant]
US 20080160564A1
· Rich
· 2008
[cited by applicant]
US 20080166327A1
· Asahara et al.
· 2008
[cited by applicant]
US 20080166751A1
· Asahara et al.
· 2008
[cited by applicant]
US 20090246875A1
· Yamanaka et al.
· 2009
[cited by applicant]
US 20090304646A1
· Sakurada et al.
· 2009
[cited by applicant]
US 20100216181A1
· Daigh et al.
· 2010
[cited by applicant]
US 20100248361A1
· Lasky et al.
· 2010
[cited by applicant]
US 20100316613A1
· Upton et al.
· 2010
[cited by applicant]
US 20110053267A1
· Nakauchi et al.
· 2011
[cited by applicant]
US 20110064705A1
· Lanza et al.
· 2011
[cited by applicant]
US 20110086424A1
· Lanza et al.
· 2011
[cited by applicant]
US 20110151554A1
· Yuo et al.
· 2011
[cited by applicant]
US 20110280861A1
· Scadden et al.
· 2011
[cited by applicant]
US 20110305675A1
· Scadden et al.
· 2011
[cited by applicant]
US 20120009618A1
· Yu et al.
· 2012
[cited by applicant]
US 20120027731A1
· Lanza et al.
· 2012
[cited by applicant]
US 20120238020A1
· Mitchell
· 2012
[cited by examiner]
US 20120238023A1
· Eto et al.
· 2012
[cited by applicant]
US 20120276063A1
· Meyer et al.
· 2012
[cited by applicant]
US 20120282228A1
· Bhasin
· 2012
[cited by applicant]
US 20120315338A1
· Li et al.
· 2012
[cited by applicant]
US 20130011924A1
· Niwa et al.
· 2013
[cited by applicant]
US 20130210141A1
· Rajesh et al.
· 2013
[cited by applicant]
US 20140037600A1
· Yu et al.
· 2014
[cited by applicant]
US 20140045265A1
· Belmonte et al.
· 2014
[cited by applicant]
US 20140086883A1
· Poncz et al.
· 2014
[cited by applicant]
US 20140127815A1
· Eto et al.
· 2014
[cited by applicant]
US 20140142102A1
· Fairfax et al.
· 2014
[cited by applicant]
US 20140205582A1
· Karsunky et al.
· 2014
[cited by applicant]
US 20140227780A1
· Nishino et al.
· 2014
[cited by applicant]
US 20140271590A1
· Feng et al.
· 2014
[cited by applicant]
US 20140315760A1
· Ratner et al.
· 2014
[cited by applicant]
US 20150004694A1
· Mayaudon et al.
· 2015
[cited by applicant]
US 20150079030A1
· Moore
· 2015
[cited by applicant]
US 20150087065A1
· Haecker
· 2015
[cited by applicant]
US 20150111296A1
· Pedersen et al.
· 2015
[cited by applicant]
US 20150140657A1
· Kimbrel et al.
· 2015
[cited by applicant]
US 20150203819A1
· Murphy et al.
· 2015
[cited by applicant]
US 20150275176A1
· Kobayashi et al.
· 2015
[cited by applicant]
US 20150313944A1
· Feng et al.
· 2015
[cited by applicant]
US 20150335682A1
· Murphy et al.
· 2015
[cited by applicant]
US 20150361398A1
· Sandler et al.
· 2015
[cited by applicant]
US 20160002586A1
· Mitchell
· 2016
[cited by applicant]
US 20160002599A1
· Eto
· 2016
[cited by applicant]
US 20160011545A1
· Kakishima et al.
· 2016
[cited by applicant]
US 20160022736A1
· Feng et al.
· 2016
[cited by applicant]
US 20160139124A1
· Newman et al.
· 2016
[cited by applicant]
US 20160145573A1
· Liu
· 2016
[cited by applicant]
US 20160168540A1
· Hirata et al.
· 2016
[cited by applicant]
US 20160177265A1
· Matsubara et al.
· 2016
[cited by applicant]
US 20160206783A1
· Dietz et al.
· 2016
[cited by applicant]
US 20160235889A1
· Pallotta et al.
· 2016
[cited by applicant]
US 20160272941A1
· Baruch et al.
· 2016
[cited by applicant]
US 20170121681A1
· Lanza et al.
· 2017
[cited by applicant]
US 20170152481A1
· Lanza et al.
· 2017
[cited by applicant]
US 20180008640A1
· Feng et al.
· 2018
[cited by applicant]
US 20190002828A1
· Lanza et al.
· 2019
[cited by applicant]
US 20190002829A1
· Li et al.
· 2019
[cited by applicant]
US 20200131475A1
· Kimbrel et al.
· 2020
[cited by applicant]
US 20200157503A1
· Lanza et al.
· 2020
[cited by applicant]
US 20200263132A1
· Lanza et al.
· 2020
[cited by applicant]
US 20250090586A1
· Feng et al.
· 2025
[cited by applicant]
US 20250099505A1
· Feng et al.
· 2025
[cited by applicant]
AU 2009244231A1
· 2009
[cited by applicant]
AU 2009244236A1
· 2009
[cited by applicant]
AU 2013201444A1
· 2013
[cited by applicant]
CN 1141061A
· 1997
[cited by applicant]
CN 1204369A
· 1999
[cited by applicant]
CN 1499980A
· 2004
[cited by applicant]
CN 1556197A
· 2004
[cited by applicant]
CN 1564864A
· 2005
[cited by applicant]
CN 1192796C
· 2005
[cited by applicant]
CN 1778929A
· 2006
[cited by applicant]
CN 101045914A
· 2007
[cited by applicant]
CN 101045915A
· 2007
[cited by applicant]
CN 101052710A
· 2007
[cited by applicant]
CN 101063110A
· 2007
[cited by applicant]
CN 101160391A
· 2008
[cited by applicant]
CN 101310007A
· 2008
[cited by applicant]
CN 101500609A
· 2009
[cited by applicant]
CN 101501185A
· 2009
[cited by applicant]
CN 101528915A
· 2009
[cited by applicant]
CN 101530427A
· 2009
[cited by applicant]
CN 101649305A
· 2010
[cited by applicant]
CN 101678079A
· 2010
[cited by applicant]
CN 101981181A
· 2011
[cited by applicant]
CN 102068686A
· 2011
[cited by applicant]
CN 102083960A
· 2011
[cited by applicant]
CN 102083963A
· 2011
[cited by applicant]
CN 102256999A
· 2011
[cited by applicant]
CN 102388130A
· 2012
[cited by applicant]
CN 102660495A
· 2012
[cited by applicant]
CN 102732483A
· 2012
[cited by applicant]
CN 102822332A
· 2012
[cited by applicant]
CN ZL200980125862A
· 2014
[cited by applicant]
CN 104328087A
· 2015
[cited by applicant]
CN 104946591A
· 2015
[cited by applicant]
CN 106434527A
· 2017
[cited by applicant]
CN 107208062A
· 2017
[cited by applicant]
CN 107429230A
· 2017
[cited by applicant]
CN 111542597A
· 2020
[cited by applicant]
CN 112280739A
· 2021
[cited by applicant]
EP 2013331A2
· 2009
[cited by applicant]
EP 2288690A2
· 2011
[cited by applicant]
EP 2291513A2
· 2011
[cited by applicant]
EP 2377923A1
· 2011
[cited by applicant]
EP 2377924A1
· 2011
[cited by applicant]
EP 2377925A1
· 2011
[cited by applicant]
EP 2426197A1
· 2012
[cited by applicant]
EP 2507359A1
· 2012
[cited by applicant]
EP 2507365A1
· 2012
[cited by applicant]
EP 2712921A1
· 2014
[cited by applicant]
JP 2002515756A
· 2002
[cited by applicant]
JP 2003533698A
· 2003
[cited by applicant]
JP 2004504834A
· 2004
[cited by applicant]
JP 2004531262A
· 2004
[cited by applicant]
JP 2004535389A
· 2004
[cited by applicant]
JP 2005511084A
· 2005
[cited by applicant]
JP 2007089432A
· 2007
[cited by applicant]
JP 2009533059A
· 2009
[cited by applicant]
JP 2011519576A
· 2011
[cited by applicant]
JP 2011519577A
· 2011
[cited by applicant]
JP 2012518415A
· 2012
[cited by applicant]
JP 2012519005A
· 2012
[cited by applicant]
JP 2013512673A
· 2013
[cited by applicant]
JP 2013512676A
· 2013
[cited by applicant]
JP 2013126423A
· 2013
[cited by applicant]
JP 5630781B2
· 2014
[cited by applicant]
JP 2015057070A
· 2015
[cited by applicant]
JP 2015061539A
· 2015
[cited by applicant]
JP 5748654B2
· 2015
[cited by applicant]
JP 2016063838A
· 2016
[cited by applicant]
NZ 518191A
· 2004
[cited by applicant]
NZ 572842A
· 2012
[cited by applicant]
WO 9517500A1
· 1995
[cited by applicant]
WO 9833891A1
· 1998
[cited by applicant]
WO 9967360A2
· 1999
[cited by applicant]
WO 0011139A1
· 2000
[cited by applicant]
WO 0136589A2
· 2001
[cited by applicant]
WO WO0188539A1
· 2001
[cited by applicant]
WO 2002010347A2
· 2002
[cited by applicant]
WO 2002092756A2
· 2002
[cited by applicant]
WO WO02089730A2
· 2002
[cited by applicant]
WO 03046141A2
· 2003
[cited by applicant]
WO 03050251A2
· 2003
[cited by applicant]
WO 2004007698A1
· 2004
[cited by applicant]
WO 2004029231A1
· 2004
[cited by applicant]
WO 2004044146A2
· 2004
[cited by applicant]
WO 2005040391A1
· 2005
[cited by applicant]
WO 2005049812A1
· 2005
[cited by applicant]
WO 2005078073A2
· 2005
[cited by applicant]
WO 2005118780A1
· 2005
[cited by applicant]
WO WO2006001954A2
· 2006
[cited by applicant]
WO WO2006050330A2
· 2006
[cited by applicant]
WO 2006090882A1
· 2006
[cited by applicant]
WO WO2006118350A1
· 2006
[cited by applicant]
WO 2006130651A2
· 2006
[cited by applicant]
WO 2007005595A1
· 2007
[cited by applicant]
WO 2007032634A1
· 2007
[cited by applicant]
WO 2007037682A1
· 2007
[cited by applicant]
WO 2007095064A2
· 2007
[cited by applicant]
WO 2007120811A2
· 2007
[cited by applicant]
WO WO2008151386A1
· 2008
[cited by applicant]
WO WO2008151390A1
· 2008
[cited by applicant]
WO 2009045360A2
· 2009
[cited by applicant]
WO 2009052389A1
· 2009
[cited by applicant]
WO 2009104825A1
· 2009
[cited by applicant]
WO WO2009122747A1
· 2009
[cited by applicant]
WO 2009120891A2
· 2009
[cited by applicant]
WO WO2009119105A1
· 2009
[cited by applicant]
WO 2009137624A2
· 2009
[cited by applicant]
WO 2009137629A2
· 2009
[cited by applicant]
WO 2010025506A1
· 2010
[cited by applicant]
WO 2010096746A1
· 2010
[cited by applicant]
WO 2010099539A1
· 2010
[cited by applicant]
WO 2011034073A1
· 2011
[cited by applicant]
WO 2011068896A1
· 2011
[cited by applicant]
WO WO2011069127A1
· 2011
[cited by applicant]
WO WO2012036257A1
· 2012
[cited by applicant]
WO WO2012145384A1
· 2012
[cited by applicant]
WO 2012157586A1
· 2012
[cited by applicant]
WO WO2012158983A2
· 2012
[cited by applicant]
WO WO2014138485A1
· 2014
[cited by applicant]
WO WO2015179301A1
· 2015
[cited by applicant]
WO WO2015191632A1
· 2015
[cited by applicant]
WO WO2016160860A1
· 2016
[cited by applicant]
WO 2020163269A1
· 2020
[cited by applicant]
Nieswandt et al., Lysis of tumor cells by natural killer cells in mice is impeded by platelets. Cancer Res. Mar. 15, 1999;59(6):1295-300.
[cited by applicant]
Rolfes et al., Platelets Fuel the Inflammasome Activation of Innate Immune Cells. Cell Rep. May 12, 2020;31(6):107615. doi: 10.1016/j.celrep.2020.107615.
[cited by applicant]
Salvagiotto et al., A Defined, Feeder-Free, Serum-Free System to Generate In Vitro Hematopoietic Progenitors and Differentiated Blood Cells from hESCs and hiPSCs. PLoS One. Mar. 18, 2011;6(3):e17829. doi: 10.1371/journa…
[cited by applicant]
Van Der Heyde et al., Platelet depletion by anti-CD41 (alphaIIb) mAb injection early but not late in the course of disease protects against Plasmodium berghei pathogenesis by altering the levels of pathogenic cytokines.…
[cited by applicant]
Huang et al., Histology of Rhesus Monkey. Guangdong Science and Technology Press. 1st edition. Jun. 2010. pp. 54-57.
[cited by applicant]
Liu et al., Hypoxia Enhances the Differentiation of Hemogenic Endothelial Cells from Human Embryonic Stem Cells through Up-regulating Wnt5a Signal. Scientia Sinica Vitae. Oct. 2013; 43(10): 877-885. DOI:10.1360/052013-2…
[cited by applicant]
Monzen et al., Terminal maturation of megakaryocytes and platelet production by hematopoietic stem cells irradiated with heavy-ion beams. Radiat Res. Jul. 2011;176(1):8-16. doi: 10.1667/rr2392.1. Epub Apr. 29, 2011.
[cited by applicant]
Xin et al., In vitro induction of cord blood CD34+cells differentiation into mature megakaryocytes and production of platelets Chinese Journal of Tissue Engineering Research. Mar. 2009; 13(10): 1976-1980.
[cited by applicant]
Choi et al., Identification of the hemogenic endothelial progenitor and its direct precursor in human pluripotent stem cell differentiation cultures. Cell Rep. Sep. 27, 2012;2(3):553-67. doi: 10.1016/j.celrep.2012.08.00…
[cited by applicant]
Jia, Cell therapy in liver diseases. People's Health Publishing House. 1st edition. Apr. 2005. pp. 188-192.
[cited by applicant]
Johnson et al., Extended storage of thawed platelets: Refrigeration supports postthaw quality for 10 days. Transfusion. Dec. 2020;60(12):2969-2981. doi: 10.1111/trf.16127. Epub Oct. 21, 2020.
[cited by applicant]
Shi et al., Comparative Medicine. 1st Edition. Shaanxi Science and Technology Press, eds. Jul. 2003; 1: 155-156. ISBN 7-5369-3549-8.
[cited by applicant]
Valeri et al., Freezing human platelets with 6 percent dimethyl sulfoxide with removal of the supernatant solution before freezing and storage at -80° C. without postthaw processing. Transfusion. Dec. 2005;45(12):1890-8…
[cited by applicant]
Wang et al., Basic Theory and Clinical Practice of Thrombosis and Hemostasis. Shanghai Science and Technology Press. 3rd Edition. Dec. 2004. pp. 63-66.
[cited by applicant]
No Author Listed, Alternative Procedures for the Manufacture of Cold-Stored Platelets Intended for the Treatment of Active Bleeding when Conventional Platelets Are Not Available or Their Use Is Not Practical. U.S. Dept.…
[cited by applicant]
Valeri et al., In vitro effects of poly-N-acetyl glucosamine on the activation of platelets in platelet-rich plasma with and without red blood cells. J Trauma. Jul. 2004;57(1 Suppl):S22-5; discussion S25. doi: 10.1097/0…
[cited by applicant]
International Search Report and Written Opinion mailed Apr. 30, 2014 for Application No. PCT/US2013/077334.
[cited by applicant]
International Preliminary Report on Patentability mailed Jul. 2, 2015 for Application No. PCT/US2013/077334.
[cited by applicant]
Extended European Search Report mailed Aug. 3, 2016 in connection with European Application No. 13865661.6.
[cited by applicant]
Extended European Search Report mailed Mar. 1, 2022 in connection with European Application No. 21196318.6.
[cited by applicant]
[No Author Listed], Correction for Wani et al., Familial hypercatabolic hypoproteinemia caused by deficiency of the neonatal Fc receptor, FcRn, due to a mutant ß 2-microglobulin gene. Proc Natl Acad Sci U S A. Jul. 5, 2…
[cited by applicant]
[No Author Listed], Life technologies, Guidelines for Maintaining Cultured Cells. Retrieved online at: https://www.lifetechnologies.com/us/en/home/references/gibco-cell-culture-basics/cell-culture-protocols/maintaining-…
[cited by applicant]
[No Author Listed], NIH, Stem Cells: Scientific Progress and Future Research Directions. National Institutes of Health, Department of Health and Human Services. pp. 1-4, Jun. 2001.
[cited by applicant]
[No Author Listed], PubChem CID 18068. Galactose-uridine-5′-diphosphate. Created Jun. 1, 2005. Last modified Aug. 27, 2022. Information retrieved from the internet: https://pubchem.ncbi.nlm.nih.gov/compound/Galactose-ur…
[cited by applicant]
Alikani et al., Nonviable human pre-implantation embryos as a source of stem cells for research and potential therapy. Stem Cell Rev. Dec. 2005;1(4):337-43.
[cited by applicant]
Amable et al., Platelet-rich plasma preparation for regenerative medicine: optimization and quantification of cytokines and growth factors. Stem Cell Res Ther. Jun. 7, 2013;4(3):67. doi: 10.1186/scrt218.
[cited by applicant]
Amarilyo et al., Increased cord serum inflammatory markers in small-for-gestational-age neonates. J Perinatol. Jan. 2011;31(1):30-2. doi: 10.1038/jp.2010.53. Epub Apr. 22, 2010.
[cited by applicant]
Andreu et al., Prevention of HLA immunization with leukocyte-poor packed red cells and platelet concentrates obtained by filtration. Blood. Sep. 1988;72(3):964-9.
[cited by applicant]
Athanasiou et al., Increased expression of the ETS-related transcription factor FLI-1/ERGB correlates with and can induce the megakaryocytic phenotype. Cell Growth Differ. Nov. 1996;7(11):1525-34.
[cited by applicant]
Baek et al., Stroma-free mass production of clinical-grade red blood cells (RBCs) by using poloxamer 188 as an RBC survival enhancer. Transfusion. Nov. 2009;49(11):2285-95.
[cited by applicant]
Bagamery et al., Are platelets activated after a rapid, one-step density gradient centrifugation? Evidence from flow cytometric analysis. Clin Lab Haematol. Feb. 2005;27(1):75-7.
[cited by applicant]
Bertolini et al., Megakaryocytic progenitors can be generated ex vivo and safely administered to autologous peripheral blood progenitor cell transplant recipients. Blood. Apr. 15, 1997;89(8):2679-88.
[cited by applicant]
Bhatia, Hematopoiesis from human embryonic stem cells. Ann N Y Acad Sci. Jun. 2007;1106:219-22.
[cited by applicant]
Bordoni et al., Hepatocyte-conditioned medium sustains endothelial differentiation of human hematopoietic-endothelial progenitors. Hepatology. May 2007;45(5):1218-28.
[cited by applicant]
Bowles et al., HOXB4 overexpression promotes hematopoietic development by human embryonic stem cells. Stem Cells. May 2006;24(5):1359-69.
[cited by applicant]
Brevini et al., No shortcuts to pig embryonic stem cells. Theriogenology. Sep. 1, 2010;74(4):544-50. doi: 10.1016/j.theriogenology.2010.04.020.
[cited by applicant]
Buta et al., Reconsidering pluripotency tests: do we still need teratoma assays? Stem Cell Res. Jul. 2013;11(1):552-62. doi: 10.1016/j.scr.2013.03.001. Review.
[cited by applicant]
Cerdan et al., Hematopoietic Differentiation. Embryonic Stem Cells. Chapter 5, pp. 53-83, (2007).
[cited by applicant]
Chang et al., Definitive-like erythroid cells derived from human embryonic stem cells coexpress high levels of embryonic and fetal globins with little or no adult globin. Blood. Sep. 1, 2006;108(5):1515-23. Epub Apr. 27…
[cited by applicant]
Chan-Ling et al., Hematopoietic stem cells provide repair functions after laser-induced Bruch's membrane rupture model of choroidal neovascularization. Am J Pathol. Mar. 2006;168(3):1031-44.
[cited by applicant]
Chen et al., A point mutation in the integrin beta 3 cytoplasmic domain (S752-->P) impairs bidirectional signaling through alpha IIb beta 3 (platelet glycoprotein IIb-IIIa). Blood. Sep. 15, 1994;84(6):1857-65.
[cited by applicant]
Chen et al., Large generation of megakaryocytes from serum-free expanded human CD34+ cells. Biochem Biophys Res Commun. Jan. 2, 2009;378(1):112-7. doi: 10.1016/j.bbrc.2008.11.019. Epub Nov. 21, 2008.
[cited by applicant]
Cheng et al., Human mesenchymal stem cells support megakaryocyte and pro-platelet formation from CD34(+) hematopoietic progenitor cells. J Cell Physiol. Jul. 2000;184(1):58-69.
[cited by applicant]
Chockalingam et al., Management of patients refractory to platelet transfusion. J Infus Nurs. Jul.-Aug. 2007;30(4):220-5. Review. Abstract Only.
[cited by applicant]
Choi et al., A common precursor for hematopoietic and endothelial cells. Development. Feb. 1998;125(4):725-32.
[cited by applicant]
Choi et al., In vitro development of a hemangioblast from a human embryonic stem cell, SNUhES#3. Life Sci. Jul. 3, 2009;85(1-2):39-45.
[cited by applicant]
Chun et al., Megakaryocyte Production from Feeder Cell-Free Cultures of Human Embryonic Stem Cells (hESC). Blood, 2009;114: Abstract 2528.
[cited by applicant]
Cibelli et al., Parthenogenetic stem cells in nonhuman primates. Science. Feb. 1, 2002;295(5556):819.
[cited by applicant]
Cibelli et al., Somatic Cell Nuclear Transfer in Humans: Pronuclear and Early Embryonic Development. ebiomed: The Journal of Regenerative Medicine. Nov. 26, 2001;2(5):25-31.
[cited by applicant]
Coppinger et al., Characterization of the proteins released from activated platelets leads to localization of novel platelet proteins in human atherosclerotic lesions. Blood. Mar. 15, 2004;103(6):2096-104.
[cited by applicant]
Dang et al., Efficiency of embryoid body formation and hematopoietic development from embryonic stem cells in different culture systems. Biotechnol Bioeng. 2002;78(4):442-453.
[cited by applicant]
Doe et al., Novel Rho kinase inhibitors with anti-inflammatory and vasodilatory activities. J Pharmacol Exp Ther. Jan. 2007;320(1):89-98. Epub Oct. 3, 2006.
[cited by applicant]
Dolzhanskiy et al., The development of human megakaryocytes: III. Development of mature megakaryocytes from highly purified committed progenitors in synthetic culture media and inhibition of thrombopoietin-induced polyp…
[cited by applicant]
Dore et al., Transcription factor networks in erythroid cell and megakaryocyte development. Blood. Jul. 14, 2011;118(2):231-9.
[cited by applicant]
Douay et al., Stem cells—a source of adult red blood cells for transfusion purposes: present and future. Crit Care Clin. Apr. 2009;25(2):383-98.
[cited by applicant]
Encabo et al., Interleukin-6 precludes the differentiation induced by interleukin-3 on expansion of CD34+ cells from cord blood. J Hematol. Apr. 2003;88(4):388-95.
[cited by applicant]
Fan et al., Megakaryocyte Production From Feeder Cell-Free Cultures of Human Embryonic Stem Cells (hESC). Blood. 2009;114(22):2528. 3 pages.
[cited by applicant]
Fedele et al., CD38 is expressed on human mature monocyte-derived dendritic cells and is functionally involved in CD83 expression and IL-12 induction. Eur J Immunol. May 2004;34(5):1342-50.
[cited by applicant]
Feng et al., Scalable generation of universal platelets from human induced pluripotent stem cells. Stem Cell Reports. Nov. 11, 2014;3(5):817-31. doi: 10.1016/j.stemcr.2014.09.010. Epub Oct. 16, 2014.
[cited by applicant]
Figueiredo et al., Generation of HLA-deficient platelets from hematopoietic progenitor cells. Transfusion. Aug. 2010;50(8):1690-701. doi: 10.1111/j.1537-2995.2010.02644.x. Epub Apr. 15, 2010.
[cited by applicant]
Furie et al., Mechanisms of thrombus formation. N Engl J Med. Aug. 28, 2008;359(9):938-49. doi: 10.1056/NEJMra0801082. Review. First 100 words only.
[cited by applicant]
Geens et al., Human embryonic stem cell lines derived from single blastomeres of two 4-cell stage embryos. Hum Reprod. Nov. 2009;24(11):2709-17.
[cited by applicant]
Giarratana et al., Ex vivo generation of fully mature human red blood cells from hematopoietic stem cells. Nat Biotechnol. Jan. 2005;23(1):69-74.
[cited by applicant]
Ginsberg et al., Inside-out integrin signaling. Curr Opin Cell Biol. Oct. 1992;4(5):766-71. Review. Abstract only.
[cited by applicant]
Gomez et al., Derivation of cat embryonic stem-like cells from in vitro-produced blastocysts on homologous and heterologous feeder cells. Theriogenology. Sep. 1, 2010;74(4):498-515. doi: 10.1016/j.theriogenology.2010.05…
[cited by applicant]
Gordon-Keylock et al., Endothelio-hematopoietic relationship: getting closer to the beginnings. BMC Biol. Dec. 28, 2011;9:88. doi: 10.1186/1741-7007-9-88.
[cited by applicant]
Grant et al., Adult hematopoietic stem cells provide functional hemangioblast activity during retinal neovascularization. Nat Med. Jun. 2002;8(6):607-12.
[cited by applicant]
Gras, et al., HLA-universal platelet transfusions prevent platelet refractoriness in a mouse model. Hum Gene Ther. Dec. 2013;24(12):1018-28. doi: 10.1089/hum.2013.074. Epub Nov. 7, 2013.
[cited by applicant]
Guerriero et al., Stromal cell-derived factor 1alpha increases polyploidization of megakaryocytes generated by human hematopoietic progenitor cells. Blood. May 1, 2001;97(9):2587-95.
[cited by applicant]
Guo et al., Hemangioblastic characteristics of fetal bone marrow-derived Flk1(+)CD31(−)CD34(−) cells. Exp Hematol. Jul. 2003;31(7):650-8.
[cited by applicant]
Hematti et al., Nonhuman primate embryonic stem cells as a preclinical model for hematopoietic and vascular repair. Exp Hematol. Sep. 2005;33(9):980-6.
[cited by applicant]
Hiroyama et al., Establishment of mouse embryonic stem cell-derived erythroid progenitor cell lines able to produce functional red blood cells. PLoS One. Feb. 6, 2008;3(2):e1544, 11 pages.
[cited by applicant]
Hottz et al., Platelets in Immune Response to Virus and Immunopathology of Viral Infections. Front Med (Lausanne). Apr. 30, 2018;5:121. doi: 10.3389/fmed.2018.00121. eCollection 2018.
[cited by applicant]
Huangfu et al., Induction of pluripotent stem cells from primary human fibroblasts with only Oct4 and Sox2. Nat Biotechnol. Nov. 2008;26(11):1269-75.
[cited by applicant]
Ireland, Visualizing Human Biology, 3rd Ed. Wiley and Sons Inc. 2008. 3 pages.
[cited by applicant]
Jarnjak-Jankovic et al., A full scale comparative study of methods for generation of functional Dendritic cells for use as cancer vaccines. BMC Cancer. Jul. 3, 2007;7:119. 9 pages.
[cited by applicant]
Jean et al., Pluripotent genes in avian stem cells. Dev Growth Differ. Jan. 2013;55(1):41-51. doi: 10.1111/dgd.12021. Review.
[cited by applicant]
Karsunky et al., Flt3 ligand regulates dendritic cell development from Flt3+ lymphoid and myeloid-committed progenitors to Flt3+ dendritic cells in vivo. J Exp Med. 2003;198(2):305-13.
[cited by applicant]
Kennedy et al., Development of the hemangioblast defines the onset of hematopoiesis in human ES cell differentiation cultures. Blood. Apr. 1, 2007;109(7):2679-87.
[cited by applicant]
Kim et al., Human peripheral blood-derived CD31+ cells have robust angiogenic and vasculogenic properties and are effective for treating ischemic vascular disease. J Am Coll Cardiol. Aug. 10, 2010;56(7):593-607. doi: 10…
[cited by applicant]
Kimura et al., Interleukin 6 is a differentiation factor for human megakaryocytes in vitro. Eur J Immunol. 1990;20:1927-31.
[cited by applicant]
Klimanskaya et al., Approaches for Derivation and Maintenance of Human Embryonic Stem Cells: Detailed Procedures and Alternatives. Essentials of Stem Cell Biology, Third Edition. Academic Press. Chapter 29, pp. 409-434,…
[cited by applicant]
Klimanskaya et al., Approaches of derivation and maintenance of human ES cells: Detailed procedures and alternatives. vol. 1: Embryonic Stem Cells. New York: Elsevier/Academic Press; 2004:437-49.
[cited by applicant]
Klimchenko et al., A common bipotent progenitor generates the erythroid and megakaryocyte lineages in embryonic stem cell-derived primitive hematopoiesis. Blood. Aug. 2009 0;114(8):1506-17. doi:10.1182/blood-2008-09-178…
[cited by applicant]
Kuter, New thrombopoietic growth factors. Blood. Jun. 1, 2007;109(11):4607-16. Epub Feb. 8, 2007. Review.
[cited by applicant]
Lagrue-Lak-Hal et al., Expression and function of the collagen receptor GPVI during megakaryocyte maturation. J Biol Chem. May 4, 2001;276(18):15316-25.
[cited by applicant]
Lechmann et al., CD83 on dendritic cells: more than just a marker for maturation. Trends Immunol. Jun. 2002;23(6):273-5.
[cited by applicant]
Li et al., [In vitro differentiation into megakaryocytes and generation of platelets from CD34+ cells of umbilical cord blood]. Zhong Nan Da Xue Xue Bao Yi Xue Ban. Oct. 2006;31(5):776-81. Chinese.
[cited by applicant]
Lin et al., Multilineage potential of homozygous stem cells derived from metaphase II oocytes. Stem Cells. 2003;21(2):152-61.
[cited by applicant]
Loges et al., Identification of the adult human hemangioblast. Stem Cells Dev. Jun. 2004;13(3):229-42.
[cited by applicant]
Lowry et al., Generation of human induced pluripotent stem cells from dermal fibroblasts. Proc Natl Acad Sci U S A. Feb. 26, 2008;105(8):2883-8. doi: 10.1073/pnas.0711983105. Epub Feb. 15, 2008.
[cited by applicant]
Lu et al., CD34+CD38− hematopoietic precursors derived from human embryonic stem cells exhibit an embryonic gene expression pattern. Blood. Jun. 1, 2004;103(11):4134-41. Epub Feb. 12, 20042
[cited by applicant]
Lu et al., GeneChip analysis of human embryonic stem cell differentiation into hemangioblasts: an in silico dissection of mixed phenotypes. Genome Biol. 2007;8(11):R240, 19 pages.
[cited by applicant]
Lu et al., Hemangioblasts from human embryonic stem cells generate multilayered blood vessels with functional smooth muscle cells. Regen Med. Jan. 2009;4(1):37-47.
[cited by applicant]
Lu et al., Megakaryocyte developmental biology platelet production regulatory system. International Journal of Blood Transfusion and Hematology. 2012; 1: 66-69.
[cited by applicant]
Lu et al., Platelets generated from human embryonic stem cells are functional in vitro and in the microcirculation of living mice. Cell Res. Mar. 2011;21(3):530-45. doi: 10.1038/cr.2011.8. Epub Jan. 11, 2011.
[cited by applicant]
Lu et al., Protocol for culturing, differentiating and expanding hES-BC cells. Supplemental Protocol. Nature Methods. 2007;4:1-3.
[cited by applicant]
Lu et al., Recombinant HoxB4 fusion proteins enhance hematopoietic differentiation of human embryonic stem cells. Stem Cells Dev. Aug. 2007;16(4):547-59.
[cited by applicant]
Luo et al., Role of Blood Flow Shear Stress in Atherosclerosis. China Modern Doctor. 2010; 9:13-14,47.
[cited by applicant]
Ma et al., Generation of functional erythrocytes from human embryonic stem cell-derived definitive hematopoiesis. Proc Natl Acad Sci U S A. Sep. 2, 2008;105(35):13087-92.
[cited by applicant]
Ma et al., Novel method for efficient production of multipotential hematopoietic progenitors from human embryonic stem cells. Int J Hematol. Jun. 2007;85(5):371-9.
[cited by applicant]
Maherali et al., Guidelines and techniques for the generation of induced pluripotent stem cells. Cell Stem Cell. Dec. 4, 2008;3(6):595-605.
[cited by applicant]
Matsumoto et al., Stepwise development of hematopoietic stem cells from embryonic stem cells. PLoS One. 2009;4(3):e4820, 10 pages.
[cited by applicant]
Mercher et al., Notch signaling specifies megakaryocyte development from hematopoietic stem cells. Cell Stem Cell. Sep. 11, 2008;3(3):314-26. doi: 10.1016/j.stem.2008.07.010.
[cited by applicant]
Minami et al., Fundamental study of producing human ES/iPS cell-derived endothelial cells. The 14
[cited by applicant]
Mitalipova et al., Human embryonic stem cell lines derived from discarded embryos. Stem Cells. 2003;21(5):521-6.
[cited by applicant]
Morikawa et al., BMP Sustains Embryonic Stem Cell Self-Renewal through Distinct Functions of Different Krüppel-like Factors. Stem Cell Reports. Jan. 12, 2016;6(1):64-73. doi: 10.1016/j.stemcr.2015.12.004.
[cited by applicant]
Munoz et al., Conventional pluripotency markers are unspecific for bovine embryonic-derived cell-lines. Theriogenology. Jun. 2008;69(9):1159-64. doi: 10.1016/j.theriogenology.2008.02.014.
[cited by applicant]
Mutreja et al., Evaluation of platelet surface glycoproteins in patients with Glanzmann thrombasthenia: Association with bleeding symptoms. Indian J Med Res. May 2017;145(5):629-634. doi: 10.4103/ijmr.IJMR_718_14.
[cited by applicant]
Nakamura, In vitro production of transfusable red blood cells. Biotechnol Genet Eng Rev. 2008;25:187-201.
[cited by applicant]
Neildez-Nguyen et al., Human erythroid cells produced ex vivo at large scale differentiate into red blood cells in vivo. Nat Biotechnol. May 2002;20(5):467-72.
[cited by applicant]
Olivier et al., Large-scale production of embryonic red blood cells from human embryonic stem cells. Exp Hematol. Dec. 2006;34(12):1635-42.
[cited by applicant]
Ozawa et al., Erythroid cells play essential roles in angiogenesis by bone marrow cell implantation. J Mol Cell Cardiol. May 2006;40(5):629-38.
[cited by applicant]
Paris et al., Equine embryos and embryonic stem cells: defining reliable markers of pluripotency. Theriogenology. Sep. 1, 2010;74(4):516-24. doi: 10.1016/j.theriogenology.2009.11.020. Review.
[cited by applicant]
Park et al., Reprogramming of human somatic cells to pluripotency with defined factors. Nature. Jan. 10, 2008;451(7175):141-6.
[cited by applicant]
Passegue et al., Normal and leukemic hematopoiesis: are leukemias a stem cell disorder or a reacquisition of stem cell characteristics? Proc Natl Acad Sci U S A. Sep. 30, 2003;100 Suppl 1:11842-9.
[cited by applicant]
Pearson et al., The stepwise specification of embryonic stem cells to hematopoietic fate is driven by sequential exposure to Bmp4, activin A, bFGF and VEGF. Development. Apr. 2008; 135(8):1525-35.
[cited by applicant]
Peerschke, Glycoprotein IIb and IIIa retention on fibrinogen-coated surfaces after lysis of adherent platelets. Blood. Dec. 1, 1993;82(11):3358-63.
[cited by applicant]
Pick et al., Differentiation of human embryonic stem cells in serum-free medium reveals distinct roles for bone morphogenetic protein 4, vascular endothelial growth factor, stem cell factor, and fibroblast growth factor…
[cited by applicant]
Pilat et al., HOXB4 enforces equivalent fates of ES-cell-derived and adult hematopoietic cells. Proc Natl Acad Sci U S A. Aug. 23, 2005;102(34):12101-6.
[cited by applicant]
Piper et al., In vivo recovery of human platelets in severe combined immunodeficient mice as a measure of platelet damage. Transfusion. Aug. 2007;47(8):1540-9. Abstract Only.
[cited by applicant]
Purpura et al., Analysis of the temporal and concentration-dependent effects of BMP-4, VEGF, and TPO on development of embryonic stem cell-derived mesoderm and blood progenitors in a defined, serum-free media. Exp Hemat…
[cited by applicant]
Qi et al., BMP4 supports self-renewal of embryonic stem cells by inhibiting mitogen-activated protein kinase pathways. Proc Natl Acad Sci U S A. Apr. 20, 2004;101(16):6027-32. Epub Apr. 9, 2004.
[cited by applicant]
Qiu et al., Globin switches in yolk sac-like primitive and fetal-like definitive red blood cells produced from human embryonic stem cells. Blood. Feb. 15, 2008;111(4):2400-8.
[cited by applicant]
Rajesh et al., Differential requirements for hematopoietic commitment between human and rhesus embryonic stem cells. Stem Cells. Feb. 2007;25(2):490-9.
[cited by applicant]
Reijo Pera et al., Gene expression profiles of human inner cell mass cells and embryonic stem cells. Differentiation. Jul. 2009;78(1):18-23. doi: 10.1016/j.diff.2009.03.004. Epub Apr. 23, 2009.
[cited by applicant]
Reubinoff et al., Embryonic stem cell lines from human blastocysts: somatic differentiation in vitro. Nat Biotechnol. Apr. 2000;18(4):399-404. Erratum in: Nat Biotechnol May 2000;18(5):559.
[cited by applicant]
Revazova et al., Patient-specific stem cell lines derived from human parthenogenetic blastocysts. Cloning Stem Cells. 2007 Fall;9(3):432-49.
[cited by applicant]
Rogers et al., Phospholipase Czeta causes Ca2+ oscillations and parthenogenetic activation of human oocytes. Reproduction. Dec. 2004;128(6):697-702.
[cited by applicant]
Rowley et al., Genome-wide RNA-seq analysis of human and mouse platelet transcriptomes. Blood. Oct. 6, 2011;118(14):e101-11.
[cited by applicant]
Santoso et al., The presence of messenger RNA for HLA class I in human platelets and its capability for protein biosynthesis. Br J Haematol. Jul. 1993;84(3):451-6. Abstract Only.
[cited by applicant]
Sauvageau et al., Overexpression of HOXB4 in hematopoietic cells causes the selective expansion of more primitive populations in vitro and in vivo. Genes Dev. Jul. 15, 1995;9(14):1753-65.
[cited by applicant]
Schenke-Layland et al., Reprogrammed mouse fibroblasts differentiate into cells of the cardiovascular and hematology lineages. Stem Cells. Jun. 2008;26(6):1537-46.
[cited by applicant]
Seiler et al., Experimental limitations using reprogrammed cells for hematopoietic differentiation. J Biomed Biotechnol. 2011;2011:895086. doi: 10.1155/2011/895086. Review.
[cited by applicant]
Seliger et al., Chemical production of excited states. Chemiluminescence of carcinogenic hydrocarbons accompanying their metabolic hydroxylation and a proposal for common active site geometries for hydroxylation. J Phys…
[cited by applicant]
Senger, Pathways to Pregnancy and Parturition. Current Conceptions, Inc., Pullman, WA. Chapter 13, pp. 221-222, (1997).
[cited by applicant]
Shinoda et al., alpha4-Integrin(+) endothelium derived from primate embryonic stem cells generates primitive and definitive hematopoietic cells. Blood. Mar. 15, 2007;109(6):2406-15.
[cited by applicant]
Springer et al., VEGF gene delivery to muscle: potential role for vasculogenesis in adults. Mol Cell. Nov. 1998;2(5):549-58.
[cited by applicant]
Stroncek et al., “Universal platelets: “A” change in dogma.” Blood. Apr. 15, 2005;105(8):3008.
[cited by applicant]
Svingen et al., Hox transcription factors and their elusive mammalian gene targets. Heredity (Edinb). Aug. 2006;97(2):88-96.
[cited by applicant]